Puma Biotechnology, Inc. - News Releases

Get News Alerts by RSS

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

12/17/2018

Puma Biotechnology Announces Top Line Results of the Phase III NALA Trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer

12/11/2018

Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

12/10/2018

Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

12/06/2018

Puma Biotechnology Presents Results from the Hormone Receptor Positive Subgroup in Phase III ExteNET Trial of Neratinib for HER2-Amplified, Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium

12/06/2018

Puma Biotechnology Presents Results of Patient Reported Outcomes in Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium

12/06/2018

Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2018 San Antonio Breast Cancer Symposium

12/03/2018

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

11/07/2018

Puma Biotechnology to Present at Credit Suisse Healthcare Conference

11/01/2018

Puma Biotechnology Reports Third Quarter 2018 Financial Results

10/18/2018

Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results

10/10/2018

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

10/02/2018

Puma Biotechnology’s Licensing Partner CANbridge Pharmaceutical Submits New Drug Application for NERLYNX® (neratinib) in China

09/20/2018

Puma Biotechnology to Present at Cantor Global Healthcare Conference

09/06/2018

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

09/04/2018

European Commission Grants Marketing Authorisation for Puma Biotechnology’s NERLYNX® (neratinib) for Extended Adjuvant Treatment of Hormone Receptor Positive HER2-Positive Early Stage Breast Cancer

08/09/2018

Puma Biotechnology Reports Second Quarter 2018 Financial Results

07/31/2018

Puma Biotechnology Files New Drug Submission for NERLYNX® in Canada

07/26/2018

Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results

07/17/2018

Puma Biotechnology and Strata Oncology Announce Collaboration to Accelerate Enrollment in Neratinib HER2 Mutation Basket Study (SUMMIT Trial)

06/29/2018

Puma Biotechnology Receives Positive CHMP Opinion Recommending Approval of NERLYNX® for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

06/26/2018

Puma Biotechnology Announces Results of CHMP Reexamination of MAA for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

06/02/2018

Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2018 ASCO Annual Meeting

05/30/2018

Puma Biotechnology to Present at Jefferies Global Healthcare Conference

05/09/2018

Puma Biotechnology Reports First Quarter 2018 Financial Results

05/08/2018

Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2018

04/25/2018

Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results

04/03/2018

Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America

04/02/2018

NCCN Guidelines for Central Nervous System Cancers Include NERLYNX® (neratinib) in Combination With Capecitabine or Paclitaxel as Treatment Options for Patients With Breast Cancer Brain Metastases

03/06/2018

Puma Biotechnology to Present at Cowen’s Annual Healthcare Conference

03/01/2018

Puma Biotechnology Reports Fourth Quarter and Full Year 2017 Financial Results

02/23/2018

Puma Biotechnology Receives Results of CHMP Formal Decision for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

02/15/2018

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results

02/07/2018

Puma Biotechnology to Present at LEERINK Partners Global Healthcare Conference

02/01/2018

Puma Biotechnology and CANbridge Life Sciences Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Greater China

01/31/2018

Puma Biotechnology Announces Publication of Results from Phase II SUMMIT ‘Basket’ Trial Evaluating Neratinib in HER2 and HER3 Mutant Cancers

01/30/2018

Puma Biotechnology and Medison Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Israel

01/29/2018

Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

01/23/2018

Puma Biotechnology Announces Results of CHMP Oral Explanation for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer